Trial intelligence / Profile preview

AIR-CF2: Aztreonam Lysinate for Inhalation in Cystic Fibrosis

NCT00104520Phase 3Completed

Sponsor
Gilead Sciences
Start
Feb 2005
Primary completion
Sep 2006
Modality
Inhalation Devices, Small Molecules
Countries
1
01

Overview

A Phase 3 trial of aztreonam in cystic fibrosis (CF), sponsored by Gilead Sciences. Started Feb 2005; status: completed.

02

Drugs

aztreonam
03

Conditions

cystic fibrosis (CF)

Beyond the preview

Go deeper on NCT00104520.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00104520.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call